Lytix Biopharma recruits Stephen Worsley as Chief Business Officer

Norwegian immuneoncology company Lytix has announced the appointment of Stephen Worsley as Chief Business Officer.
Stephen Worsley is a pharmaceutical executive with over 25 years of knowledge in business development in the biopharmaceutical and drug discovery/development market. As a business development executive, Worsley has led negotiation of transformative and award-winning technology and product partnerships for leading therapeutics companies.
Lytix Biopharma is a clinical-stage biotech company developing novel cancer immunotherapies, an area within cancer therapy which is aimed at activating the patient’s immune system to fight cancer. The company’s technology is based on pioneering research in ‘host defence peptides’.
Øystein Rekdal, CEO of Lytix said, “As we plan for continued progress to reach several important milestones in our development programs at Lytix, we are excited to welcome Stephen Worsley to our management team at Lytix Biopharma. His extensive experience in business development where he has led various strategic partnerships, acquisitions, equity investments, clinical collaborations, and out licensing transactions, will play a central role as we advance our exciting pipeline of immunoactivating drugs for cancer through further clinical development and towards market, with several potential partnering opportunities along the way.”